مكتبة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience.

Authors : Zengin Ersoy G; Pediatric Hematology Oncology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.; Ayçiçek A

Subjects: Deferasirox/Deferasirox/Deferasirox/*administration & dosage ; Deferasirox/Deferasirox/Deferasirox/*pharmacokinetics ; Thalassemia/Thalassemia/Thalassemia/*blood

Source: Pediatric hematology and oncology [Pediatr Hematol Oncol] 2021 Sep; Vol. 38 (6), pp. 555-563. Date of Electronic Publication: 2021 Mar 22.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8700164 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.

Authors : Tripathy I; Department of Paediatric Medicine, Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India.; Panja A

Subjects: Deferasirox*/Deferasirox*/Deferasirox*/adverse effects ; Deferasirox*/Deferasirox*/Deferasirox*/therapeutic use ; Deferiprone*/Deferiprone*/Deferiprone*/adverse effects

Source: Hemoglobin [Hemoglobin] 2021 Sep; Vol. 45 (5), pp. 296-302. Date of Electronic Publication: 2021 Nov 10.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The effect of deferasirox on endocrine complications in children with thalassemia.

Authors : Bilgin BK; Department of Pediatric Hematology, Ankara Dışkapı Child Health and Diseases Hematology Oncology Training and Research Hospital, Ankara, Turkey.; Yozgat AK

Subjects: Deferasirox*/Deferasirox*/Deferasirox*/administration & dosage ; Deferasirox*/Deferasirox*/Deferasirox*/adverse effects ; Splenectomy*

Source: Pediatric hematology and oncology [Pediatr Hematol Oncol] 2020 Sep; Vol. 37 (6), pp. 455-464. Date of Electronic Publication: 2020 Mar 05.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8700164 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy.

Authors : Manganas K; Thalassaemia and Sickle Cell Department, Hippokration General Hospital, Athens, Greece.; Delicou S

Subjects: Anemia, Sickle Cell*/Anemia, Sickle Cell*/Anemia, Sickle Cell*/complications ; Anemia, Sickle Cell*/Anemia, Sickle Cell*/Anemia, Sickle Cell*/therapy ; Iron Chelating Agents*/Iron Chelating Agents*/Iron Chelating Agents*/therapeutic use

Source: Hemoglobin [Hemoglobin] 2022 Mar; Vol. 46 (2), pp. 114-117. Date of Electronic Publication: 2022 Sep 07.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Perforated Duodenal Ulcer Associated with Deferasirox in a Child with β-Thalassemia Major.

Authors : Zahra A; Pediatric Hematology Unit, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait.; Ragab A

Subjects: Duodenal Ulcer*/Duodenal Ulcer*/Duodenal Ulcer*/complications ; Duodenal Ulcer*/Duodenal Ulcer*/Duodenal Ulcer*/drug therapy ; Iron Overload*/Iron Overload*/Iron Overload*/diagnosis

Source: Hemoglobin [Hemoglobin] 2021 Sep; Vol. 45 (5), pp. 335-337. Date of Electronic Publication: 2022 Jan 03.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Report

Acute hyperammonemia in children under deferasirox treatment: cutting the Gordian knot.

Authors : Martinelli D; a Division of Metabolism and Research Unit of Metabolic Biochemistry , IRCCS Bambino Gesù Children's Hospital , Rome , Italy.; b Genetics and Rare Diseases Research Division , IRCCS Bambino Gesù Children's Hospital , Rome , Italy.

Subjects: Ammonia/Ammonia/Ammonia/*blood ; Deferasirox/Deferasirox/Deferasirox/*adverse effects ; Hyperammonemia/Hyperammonemia/Hyperammonemia/*chemically induced

Source: Clinical toxicology (Philadelphia, Pa.) [Clin Toxicol (Phila)] 2019 May; Vol. 57 (5), pp. 375-377. Date of Electronic Publication: 2018 Nov 16.Publisher: Informa Healthcare Country of Publication: England NLM ID: 101241654 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.

Authors : Karimi M; a Hematology Research Centre, Shiraz University of Medical Sciences , Shiraz , Iran.; Arandi N

Subjects: Benzoates/Benzoates/Benzoates/*therapeutic use ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*therapeutic use ; Iron Overload/Iron Overload/Iron Overload/*drug therapy

Source: Hemoglobin [Hemoglobin] 2015; Vol. 39 (5), pp. 327-9. Date of Electronic Publication: 2015 Jun 26.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.

Authors : Vlachaki E; a Adult Thalassemia Unit, 2nd Department of Internal Medicine , Aristotle University, Hippokration Hospital , Thessaloniki , Greece.; Agapidou A

Subjects: Benzoates/Benzoates/Benzoates/*therapeutic use ; Cardiomyopathies/Cardiomyopathies/Cardiomyopathies/*drug therapy ; Cardiomyopathies/Cardiomyopathies/Cardiomyopathies/*etiology

Source: Hemoglobin [Hemoglobin] 2015; Vol. 39 (5), pp. 299-304. Date of Electronic Publication: 2015 Jul 15.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Predictors of non-adherence to follow-up visits and deferasirox chelation therapy among jordanian adolescents with Thalassemia major.

Authors : Al-Kloub MI; 1Department of Maternal, Child and Family Health, The Hashemite University, Zarqa, Jordan.; A Bed MA

Subjects: Chelation Therapy* ; Patient Compliance*; Benzoates/Benzoates/Benzoates/*therapeutic use

Source: Pediatric hematology and oncology [Pediatr Hematol Oncol] 2014 Oct; Vol. 31 (7), pp. 624-37. Date of Electronic Publication: 2014 Aug 12.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8700164 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.

Authors : Alavi S; 1Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Ebadi M

Subjects: Chelation Therapy*/Chelation Therapy*/Chelation Therapy*/adverse effects; Benzoates/Benzoates/Benzoates/*therapeutic use ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*therapeutic use

Source: Pediatric hematology and oncology [Pediatr Hematol Oncol] 2014 Feb; Vol. 31 (1), pp. 76-86. Date of Electronic Publication: 2014 Jan 02.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8700164 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience.

Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.

The effect of deferasirox on endocrine complications in children with thalassemia.

Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy.

Perforated Duodenal Ulcer Associated with Deferasirox in a Child with β-Thalassemia Major.

Acute hyperammonemia in children under deferasirox treatment: cutting the Gordian knot.

Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.

Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.

Predictors of non-adherence to follow-up visits and deferasirox chelation therapy among jordanian adolescents with Thalassemia major.

Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.

اتصل بنا

اتبع